Trawsfynydd Therapeutics Inc. has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Researchers from Yangzhou University presented the discovery and preclinical characterization of LysZX4-NCA, a new endolysin therapeutic being developed for the treatment of multidrug-resistant highly virulent Klebsiella pneumoniae (MDR-hvKP) infections.
Benzothiozinone (BTZ) compounds are among the new entities under development for their antimycobacterial activity, but information on their efficacy in acute tuberculosis (TB) infection models is still lacking.
Pseudomonas aeruginosa uses the quorum sensing (QS) system to regulate virulence factors expression and biofilm development. Researchers from Jinan University reported on novel inhibitors of P. aeruginosa transcriptional activator proteins LasR and LasB.
Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the vector-borne parasites Trypanosoma brucei gambiens or Trypanosoma brucei rhodesiense. Despite the recent approval of fexinidazole, novel antitrypanosomal agents are needed to attain its targeted eradication by 2030.
University of Alberta has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections.
Sail Biomedicines Inc. has received two grants from the Bill & Melinda Gates Foundation to advance the company's Endless RNA (eRNA) platform to develop secreted monoclonal antibodies and vaccines for malaria.
Researchers have identified a new class of antibiotics that works by blocking the transportation of lipopolysaccharide (LPS) to the outer membrane of the gram-negative bacterium Acinetobacter baumannii. The most advanced member of the class, zosurabalpin (RG-6006, Roche AG), was effective against multiple A. baumannii strains, including carbapenem-resistant and multidrug-resistant strains.
RSS
